Summary by Moomoo AI
TransCode Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024, where several key proposals were voted upon. The meeting saw the election of four directors, Philippe P. Calais, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, each for a one-year term. Additionally, stockholders approved an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares. The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. However, the proposal for a reverse stock split of common stock by a ratio between 1-for-2 and 1-for-40 was not approved. An adjournment proposal was passed in case there were insufficient votes to approve the reverse stock split or the stock plan amendment, but it was not needed as the latter was approved. The total number of shares entitled to vote was 6,108,053, with 2,392,577 shares present or represented by proxy.
